We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Mayo Clinic

Poster Abstracts - PROGNOSIS AL AMYLOIDOSIS

Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens PA106 (#35)

Time to next treatment is longer in patients with a haematological complete response who are FLC-MS negative vs. positive PA107 (#76)

Incidence of Second Primary Malignancies in Patients with AL amyloidosis and The Impact of Disease Stage and Therapies PA108 (#95)

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The 12-year Experience of Cleveland Clinic  PA109 (#96)

Epidemiological perspectives of amyloidosis in Argentina: results of an analysis of incidence and mortality in a population affiliated to a Medical Care Program PA110 (#108)

Clinical Features of AL Amyloidosis Patients Harboring Clonal Hematopoiesis of Indeterminate Potential PA111 (#131)

Thrombotic and Bleeding complications in patients with AL Amyloidosis PA112 (#143)

Evaluation of Minimal Residual Disease using Next Generation Flow Cytometry in patients with AL amyloidosis PA113 (#156)

Is the Cardiac Amyloidosis Artificial Intelligence Electrocardiography (CA-AI-ECG) model useful in predicting outcomes in Multiple Myeloma (MM) patients without known Amyloidosis undergoing Autologous Stem Cell Transplant (ASCT)? PA114 (#160)

Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-based Therapy. PA115 (#186)

Clinical Factors Associated with Early Sudden Unexpected Death in Systemic AL Amyloidosis: Insights from 138 Cases OA11 (#209)

Re-evaluation of Mayo 2004 and Revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies PA117 (#268)

Validating the performance of renal staging in AL amyloidosis patients undergoing autologous stem cell transplantation PA118 (#280)

Clinical profile and treatment outcomes in primary (AL) amyloidosis from low- and middle-income country (LMIC) PA119 (#299)

Mortality patterns among patients with cardiac amyloidosis in a tertiary care center in Latin America PA120 (#332)

Predictive value of free light chain burden in patients newly diagnosed with AL amyloidosis treated with CyBorD or DaraCyBorD PA121 (#348)

Inclusion criteria of clinical trials select patients with AL amyloidosis with favorable outcome and exclude almost one half of the real-life population. PA122 (#354)

Long-term evaluation of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry PA123 (#355)

Predictors of timely and deep renal responses in AL amyloidosis PA124 (#361)

Predictors of timely and deep cardiac responses in AL amyloidosis PA125 (#367)

Long-term hematologic remission in Immunoglobulin Light Chain (AL) Amyloidosis PA127 (#392)

Sustained paradoxical vasodilation and blood pressure lowering in response to sympathetic stimulation as markers of disease severity and poor survival in primary AL amyloidosis. PA128 (#454)

A predictive model for day-100 transplant-related mortality in AL amyloidosis  PA129 (#456)

IgM Immunoglobulin light chain amyloidosis: the quest for prognostic biomarkers in a rare disease with two distinct clonal phenotypes PA130 (#467)

Outcomes of patients with newly diagnosed light chain amyloidosis according to eligibility for clinical trials: Experience of a single institution PA131 (#468)

A EUropean REgistry and sample sharing networK to promote the diagnosis and management of light chain Amyloidosis: The EUREKA study PA132 (#490)

Real-life experience on light chain cardiac amyloidosis: delay in diagnosis is still a major issue PA133 (#491)

Clinical implications of genetic interphase fluorescence in situ hybridization aberrations in systemic light chain amyloidosis PA134 (#494)

Functional Capacity in Light Chain Amyloid Cardiomyopathy: Prognostic Value and Changes With Therapy PA135 (#543)

Prognostic significance of circulating tumor cells assessed with next generation flow cytometry in patients with AL amyloidosis PA136 (#550)